Cancer gene discovery has relied extensively on analyzing tumors for gains and losses to reveal the location of oncogenes and tumor suppressor genes, respectively. Deletions of 1p36 are extremely common genetic lesions in human cancer, occurring in malignancies of epithelial, neural, and hematopoietic origin. Although this suggests that 1p36 harbors a gene that drives tumorigenesis when inactivated, the identity of this tumor suppressor has remained elusive. Here we use chromosome engineering to generate mouse models with gain and loss of a region corresponding to human 1p36. This approach functionally identifies chromodomain helicase DNA binding domain 5 (Chd5) as a tumor suppressor that controls proliferation, apoptosis, and senescence via the p19 Arf /p53 pathway. We demonstrate that Chd5 functions as a tumor suppressor in vivo and implicate deletion of CHD5 in human cancer. Identification of this tumor suppressor provides new avenues for exploring innovative clinical interventions for cancer.
INTRODUCTION
Identifying cancer genes and understanding how they contribute to tumorigenesis are critical steps in controlling cancer. Although progress has been made with oncogenes, success has been limited with tumor suppressors. Most tumor suppressor genes identified thus far were found by using positional cloning of genes involved in human hereditary cancer syndromes, including retinoblastoma (Friend et al., 1987; Lee et al., 1987 ), Wilm's tumor (Call et al., 1990; Gessler et al., 1990) , neurofibromatosis type I (Cawthon et al., 1990; Wallace et al., 1990) , colorectal cancer (Fearon et al., 1990) , and breast cancer (Miki et al., 1994; Wooster et al., 1995) . However, most cancers involve spontaneous mutations; therefore, key tumor suppressors have likely eluded detection using these classical approaches.
More recently, systematic approaches to scan the genome for chromosomal gains and losses have been used to identify cancer genes. Since end-stage tumors are typically used in these studies, a limitation of this approach is that a plethora of genomic alterations are usually detected, making it difficult to identify events that initiate the tumorigenic process.
Despite these challenges, analyses of sporadic cancers have located commonly deleted regions, suggesting that genes in these intervals encode proteins that protect from malignancy. The short arm of human chromosome 1 (1p), for example, is frequently deleted in human cancer, with 1p36 deletion being the most common lesion. 1p36 deletions were first reported in neuroblastoma in 1977 (Brodeur et al., 1977) and have since been confirmed by others (White et al., 1995; White et al., 2005) . Other neural-related malignancies associated with 1p36 deletions include meningioma (Piaskowski et al., 2005) , melanoma (Poetsch et al., 2003) , pheochromocytoma (Moley et al., 1992) , and oligodendroglioma (Bello et al., 1995) . 1p36 is also deleted in hematopoietic malignancies including acute myelogenous leukemia (AML) (Mori et al., 2003) , chronic myelogenous leukemia (CML) (Mori et al., 1998) , and non-Hodgkin's lymphoma (Melendez et al., 2003) as well as in epithelial malignancies including those of the thyroid (Kleer et al., 2000) , colon (Praml et al., 1995) , cervix (Cheung et al., 2005) , and breast (Bieche et al., 1993) . These data suggest that one or more tumor suppressor genes mapping to 1p36 are lost or inactivated in a variety of human cancers. Identifying the 1p36 tumor suppressor and determining how its encoded protein suppresses malignancy may reveal an underlying molecular mechanism that protects against diverse types of cancer. However, the 1p36 tumor suppressor has remained elusive.
In this report, we identify a tumor suppressor mapping to 1p36. By using chromosome engineering (RamirezSolis et al., 1995) (reviewed in Mills and Bradley [2001] ), Table S1 and Figure S1 for details). (C) Gene targeting at D4Mit190 resulted in integration of a loxP site (triangle), a neomycin resistance cassette (N), the 5 0 half of the hprt locus (5 0 ), and the Tyrosinase gene (Ty) at the endogenous (wild-type, wt) D4Mit190 locus (upper). Targeting was assessed by Southern analysis of NdeI (Nd)-digested DNA from G418-resistant (G R ) clones by using the 1.5 kb HpaI gap probe; a 16.2 kb fragment is diagnostic for singly targeted (st) clones (lower). E, endogenous; T, targeted alleles.
we established mouse strains with a gain and loss of a genomic interval corresponding to human 1p36 and used these models to identify a 4.3 Mb region that encodes a potent regulator of proliferation, cellular senescence, apoptosis, and tumorigenesis. We determined that Chd5 is the gene within this interval that functions as a tumor suppressor and found that CHD5 is frequently deleted in human cancer. These findings identify CHD5 as a novel tumor suppressor mapping to 1p36 and provide functional evidence for its molecular mechanism in cancer.
RESULTS

Generation of Mouse Strains with Rearrangements Corresponding to Human 1p36
To functionally identify novel tumor suppressor genes mapping to human 1p36, we generated mouse strains with deletions (also called deficiencies, df) or duplications (dp) of this region. df heterozygous and dp heterozygous mice have decreased and increased dosage of genes mapping within the rearranged interval, respectively, and therefore provide genetic models for functionally characterizing genes mapping to human 1p36.
Mouse D4Mit190-D4Mit51 (D4Mit190-51) maps to human 1p36 (Figures 1A and 1B ; see Figure S1 and Table  S1 in the Supplemental Data available with this article online). df and dp alleles of this interval were generated by using chromosome engineering in mouse embryonic stem (ES) cells (Figures 1C-1E ; Figure S2 ). Targeting at D4Mit190 occurred with a frequency of 30.7%, and germline competent clones were targeted at D4Mit51 with an efficiency of 36.1% ( Figures 1C and 1D ). Eleven doubly targeted clones were electroporated with a Cre-expressing construct, and clones were grown in media containing HAT to select for rearrangements ( Figure 1E ; Figure S2B ). Drug selection revealed that four clones were df heterozygous and seven were df/dp, indicating that targeting had occurred in cis and trans, respectively ( Figure 1E ; Figure S2B ).
Two different df/dp clones were established as mouse strains and offspring genotyped by PCR. Whereas df heterozygous mice (n = 41) were generated out of eight litters, dp heterozygous weanling mice were not obtained, even though the dp heterozygous allele should have been transmitted to half of the Agouti progeny. When embryos from similar crosses were harvested during late gestation, however, df heterozygous (n = 22) and dp heterozygous (n = 20) progeny were obtained ( Figure 1F ). These observations indicate that deficiency of D4Mit190-51 is tolerated during embryonic development but that duplication of this region causes perinatal lethality. dp Heterozygous MEFs Have Decreased Proliferation and Enhanced Senescence To evaluate the cellular phenotype dp heterozygous mice, mouse embryonic fibroblasts (MEFs) from 13.5 day embryos (E13.5) from wild-type X df/dp matings were assayed for proliferation (Figure 2A ). While wild-type MEFs proliferated robustly, dp heterozygous MEFs had reduced proliferative potential. To investigate this defect further, flow cytometry was used to determine the population of cells in different stages of the cell cycle ( Figure S3 ). While 16.9% of the wild-type MEF population was in G2/M, 25.9% of the dp heterozygous MEF population was in G2/M. Consistent with the inability of dp heterozygous MEFs to proliferate, these cells expressed senescenceassociated b-galactosidase (SA-b-gal) activity, a marker of senescent cells ( Figure 2B ) (Dimri et al., 1995) . Whereas very few senescent cells were detected in early passage wild-type or df heterozygous cultures, a significant increase in the number of senescent cells was present in dp heterozygous cultures ( Figure S4 ). These analyses indicate that duplication of D4Mit190-51 dramatically compromises proliferation and enhances cellular senescence.
df Heterozygous MEFs Have Enhanced Proliferation, Immortalize, and Form Foci Spontaneously We found that df heterozygous MEFs had significantly enhanced proliferation compared to wild-type cells (Figure 2A ). Flow cytometry indicated that, while 16.9% of the wild-type MEF population was in G2/M, only 11.9% of the df heterozygous population was in this phase of the cell cycle ( Figure S3 ).
Whereas wild-type and dp heterozygous MEFs could only be serially passaged eight to ten times, df heterozygous MEFs could be passaged extensively (i.e., 48 times to date), indicating that immortalized cells are easily selected for in the df heterozygous culture ( Figure 2C , left). To determine if loss of the wild-type allele accompanies immortalization, we used simple sequence length polymorphism (SSLP) PCR ( Figure 2C , right). Both wild-type and df alleles were detectable in early passage MEFs from F1 df heterozygous embryos, as was also the case with immortalized df heterozygous cells at passage 37.
When cells were grown at high density to assess contact inhibition, wild-type cells formed monolayers, whereas df heterozygous cells formed foci with a frequency of approximately 10 À5 ( Figure 2D ). These findings (D) Gene targeting in the st clone shown in (A) was performed to modify endpoint D4Mit51 to yield doubly targeted (dt) clones. Only the Trans-targeting event (in which both targeting events occur on different homologs) is shown here (cis events are depicted in Figure S2 ). The loxP site, a puromycin resistance cassette (P), the 3 0 half of the hprt locus (3 0 ), and an Agouti transgene (Ag) were integrated at the D4Mit51 locus (upper). Accurate targeting of puromycin-resistant (P R ) clones was assessed by Southern analysis of SpeI (Sp)-digested DNA by using the 1.3 kb SacI gap probe; a 5.2 kb fragment is diagnostic for dt clones (lower).
(E) Cre-mediated recombination. trans-targeted dt clones generated hypoxanthine aminopterin thymidine (HAT)-resistant (H R ), G R , P R df/dp clones.
(F) PCR of late-stage embryos from df/dp X wild-type matings identifies wild-type (lanes 1 and 6), df heterozygous (lanes 4, 5, and 7), and dp heterozygous (lanes 2 and 3) progeny. M, l BstEI marker; d, water control. Drug resistance gained in a particular step is underlined. Figure 2 . Phenotype of df Heterozygous and dp Heterozygous MEFs (A) Proliferation assay in wild-type (black), dp heterozygous (blue), and df heterozygous (red) MEFs. Error bars are shown.
(B) Senescence assay of passage 4 MEFs (for quantitation, see Figure S4 ). Scale bar, 0.2 mm.
indicate that heterozygosity of D4Mit190-51 leads to enhanced proliferation, sensitivity to immortalization, and spontaneous foci formation.
Deletion of D4Mit190-51 Causes Hyperproliferation, whereas Duplication of This Region Causes Apoptosis In Vivo df heterozygous mice were grossly normal and indistinguishable from wild-type progeny at E17.5; however, df heterozygous adult mice frequently developed hyperplasia in a variety of tissues (Table S2 ). In contrast, late gestation dp heterozygous embryos had striking developmental abnormalities (exencephaly, eye defects [microphthalmia], a conspicuous curling of the tail) that caused them to die perinatally ( Figure S5A ). Histological analysis revealed that the neural tube contained a large number of cells that appeared apoptotic ( Figure S5B ). Indeed, TUNEL assays on sagittal sections detected a marked increase in the number of apoptotic cells in tissues of dp heterozygous embryos, which was particularly notable in the neural tube ( Figure 3A ). This analysis indicates that deletion and duplication of D4Mit190-51 causes hyperproliferation and apoptosis, respectively, providing in vivo evidence that this region is a potent regulator of cellular proliferation and survival.
The dp Heterozygous Phenotype Is Caused by Enhanced Gene Dosage To test the hypothesis that the excessive apoptosis of dp heterozygous mice was caused by enhanced dosage of the D4Mit190-51 interval, we evaluated the phenotype of E17.5 df/dp embryos ( Figure 3B ). dp heterozygous embryos had striking developmental defects, as shown above. df/df embryos were not obtained in these crosses, suggesting that D4Mit190-51 homozygosity is embryonic lethal. Importantly, df/dp embryos were indistinguishable from wild-type controls, demonstrating that the df allele functionally rescues the developmental defects characteristic of dp heterozygous embryos. In addition, df/dp mice (n = 11) obtained from df/dp intercrosses were viable and fertile ( Figure 3B , lower left). Furthermore, proliferation of df/dp MEFs was essentially equivalent to that of wild-type MEFs ( Figure 3C ). These analyses provide direct genetic evidence that both the enhanced apoptosis of dp heterozygous mice in vivo and the reduced proliferation of dp heterozygous MEFs in culture are due to increased dosage of D4Mit190-51. Therefore, proliferation, apoptosis, and senescence are tightly regulated by dosage of this region.
The dp Heterozygous Phenotype Is p53 Dependent To examine whether the phenotype of dp heterozygous cells was p53 dependent, we used a short hairpin RNA (shRNA) specific for p53 to knock down p53 in dp heterozygous MEFs ( Figure 4A ). Whereas control (GFP-infected) dp heterozygous cultures proliferated poorly, dp heterozygous cultures expressing a p53 shRNA proliferated robustly. We next asked whether p53 deficiency could protect dp heterozygous mice from apoptosis in vivo and rescue their perinatal lethality. Progeny from df/dp and p53 +/À intercrosses produced viable dp heterozygous; p53 +/À newborns with developmental defects, but these defects were significantly less severe than those of dp heterozygous mice ( Figure 4B ), indicating that p53 heterozygosity partially rescues the apoptotic phenotype. Although many of these mice became runted, developed ataxia, and did not survive until weaning, some dp heterozygous; p53 +/À mice survived to adulthood. Subsequent df/dp; p53 +/À X p53 +/À crosses produced viable, fertile dp heterozygous; Figure 4B , lower). These analyses provide direct genetic evidence that both the proliferative and apoptotic defects of dp heterozygous cells are rescued by p53 deficiency, indicating that increased dosage of D4Mit190-51 modulates proliferation, senescence, and apoptosis in a p53-dependent manner.
p53 Is Compromised in df Heterozygous Cells
An important advantage of chromosome engineering is that the phenotype caused by gain and loss of the same genomic region can be directly compared and contrasted. Since increased dosage of D4Mit190-51 enhances p53 function, we reasoned that reduced dosage of this region should lead to compromised p53 function. Although realtime PCR revealed that p53 expression at the transcript level was essentially equivalent in wild-type and df heterozygous MEFs, western analysis revealed that basal p53 expression at the protein level was compromised in df heterozygous cells ( Figure 4C ). Accordingly, expression of the p53 target genes p21 and Mdm-2 was reduced in df heterozygous MEFs ( Figure 4C , left). To investigate if df heterozygous cells could induce p53 in response to DNA damage, MEFs were treated with adriamycin and p53 expression assessed by western analysis ( Figure 4C , right). df heterozygous cells were able to induce p53 as efficiently as wild-type cells. However, p53 levels began to decline in df heterozygous cells 24 hr following DNA damage. To extend these findings, we analyzed df heterozygous, wild-type, and dp heterozygous MEFs for p53 expression by immunofluorescence and found a direct correlation between dosage and p53 expression ( Figure 4D ). These analyses revealed that p53 expression was compromised and enhanced in df heterozygous and dp heterozygous cells, respectively, demonstrating that D4Mit190-51 positively regulates p53.
(C) Immortalization assay (left) and PCR (right) using SSLP primers specific for the df allele (df), primers that differentiate between the wild-type (B6 mouse strain) and the df (129Sv mouse strain) alleles (D4Mit308), and control primers (actin). DNA from the 129Sv strain (lane 2), the B6 strain (lane 3), F1 (B6, 129Sv) dp heterozygous mice (lane 4), and passage 37 (i.e., immortalized) dp heterozygous cells from F1 mice ( Rescues the dp Heterozygous Phenotype (A) TUNEL assay. (B) Whole-mount analysis (upper) and genotyping by PCR (lower left) of E17.5 embryos from df/dp X df heterozygous matings. Lane 1, negative control; lane 2, wild-type; lane 3, df heterozygous; lanes 4 and 5, dp heterozygous; lane 6, df/dp. df/dp mice are viable and fertile as adults (lower right). (C) Proliferation of dp heterozygous and df/dp MEFs. Error bars are shown.
Identification of the Proliferation-Suppressing Gene Mapping to D4Mit190-51 D4Mit190-51 includes 52 annotated genes (see Figure 1B and Table S1 ). Reasoning that increased dosage of a single gene within this region modulates proliferation, we screened for genes that would functionally rescue the proliferation defect of dp heterozygous cells when depleted. Proof of principal experiments for this screen were that the proliferation defect of dp heterozygous MEFs could be rescued by the df allele as well as by shRNA-mediated knockdown of p53 (see Figures 3B and 4A ), indicating that reducing dosage of D4Mit190-51 restores proliferation and that RNAi is effective in dp heterozygous MEFs.
To prioritize between candidate genes, we assessed the Gene Ontology (GO) terms and selected a number of candidates (see Table S1 ). Retroviral constructs encoding shRNAs specific for Camta1, Chd5, Dffb, Dnajc, Errfi1, Hes2, Hkr3a, Kcnabb, p73, Per3, Prdm16 were generated (Table S3 ) and constructs were tested for their ability to knock down their targets in wild-type cells by real-time PCR ( Figure 5A ; data not shown). Next, a number of these hairpins were scored for their ability to bypass the proliferation defect of dp heterozygous cells ( Figure 5B ; data not shown). dp heterozygous MEFs infected with shRNA constructs specific for Kcnabb, Camta1, or Dnajc proliferated poorly and were indistinguishable from those infected with the GFP control ( Figure 5B ; data not shown). dp heterozygous MEFs expressing p73 shRNA constructs proliferated even more poorly than dp heterozygous GFP controls, indicating that p73 deficiency exacerbated rather than rescued the dp heterozygous phenotype ( Figure S6 ; A.B. and A.A.M., unpublished data). In contrast, two distinct shRNA constructs specific for the chromodomain helicase DNA binding protein 5 (Chd5) efficiently rescued the proliferative defect of dp heterozygous MEFs ( Figure 5B) . Importantly, the extent of knockdown correlated well with the efficiency of rescue. The most efficient Chd5 hairpin, shChd5-2, restored proliferation of dp heterozygous cells nearly as well as, but subsequent to, p53 knockdown (data not shown). This suggests that p53 is genetically downstream of Chd5, consistent with the ability of p53 deficiency to rescue the phenotype of dp heterozygous cells in culture and in vivo, respectively.
The ability of Chd5 knockdown to restore proliferation in dp heterozygous cells indicates that enhanced dosage of Chd5 suppresses proliferation of dp heterozygous MEFs. We also tested whether knockdown of Chd5 could enhance proliferation in wild-type primary cells ( Figure S7 ). As was found with dp heterozygous MEFs, wild-type cells in which Dnajc was knocked down proliferated similarly to GFP-infected cells. In contrast, Chd5 knockdown enhanced proliferation of wild-type MEFs, as was also the case when p53 was knocked down in wild-type cells ( Figure S8 ). These results indicate that Chd5 is the gene within the D4Mit190-51 interval encoding a negative regulator of proliferation that induces potent tumor-suppressive mechanisms.
Chd5 Positively Regulates p53-Mediated Pathways
We next tested whether wild-type cells in which Chd5 was specifically depleted by using RNAi phenocopy df heterozygous cells in their inability to modulate p53 ( Figure 5C ; data not shown). Expression of Chd5 was reduced in both df heterozygous MEFs and in wild-type cells in which Chd5 was knocked down. Both df heterozygous and wild-type shChd5 MEFs expressed p53 transcript at levels that were essentially equivalent to that of wild-type GFP cells, whereas RNAi-mediated knockdown of depleted p53 expression and compromised expression of the p53 target genes p21, Mdm-2, PUMA, Bax, and PML. Whereas wild-type GFP MEFs expressed these p53 target genes robustly, expression was significantly reduced in both df heterozygous and wild-type shChd5-2 MEFs. Importantly, p53 transactivation in wild-type MEFs in which Chd5 was knocked down paralleled that of df heterozygous cells, indicating that Chd5 is the gene within the D4Mit190-51 interval that modulates p53. These analyses demonstrate that p53 is compromised when Chd5 is depleted, indicating that Chd5 positively regulates p53-mediated pathways.
Chd5 Suppresses Transformation
Since p53 deficient cells are susceptible to oncogenic transformation and both engineered heterozygosity of D4Mit190-51 and specific knockdown of Chd5 compromise p53 function, we assessed if oncogenic Ras could transform Chd5-compromised cells. First, wild-type GFP, wild-type shDnajc, wild-type shp53, df heterozygous, and wild-type shChd5-2 cells were infected with retrovirus expressing RasV12 and the proliferation phenotype analyzed ( Figure 6A ). Whereas wild-type GFP MEFs expressing oncogenic Ras became senescent, wild-type cells in which p53 had been knocked down proliferated robustly in response to Ras. Importantly, Ras induced robust proliferation both in df heterozygous MEFs and in wild-type MEFs in which Chd5 had been knocked down. Ras induced proliferation more effectively in cells in which Chd5 was knocked down as compared to df heterozygous cells, suggesting that RNAi reduced Chd5 levels more extensively than that achieved by engineered heterozygosity of Chd5.
To determine if Ras could transform Chd5-compromised cells, colony assays were performed in Ras-expressing cells ( Figure S9 ). Both df heterozygous and p53 knockdown cells were readily transformed by oncogenic Ras, whereas Ras was not able to transform wild-type GFP cells ( Figure S9A ). Furthermore, specific knockdown of Chd5 rendered wild-type MEFs susceptible to transformation ( Figure S9B ). We extended this finding by assessing anchorage-independent growth of Ras-expressing cells in soft agar ( Figure 6B ). Whereas wild-type GFP MEFs expressing oncogenic Ras were incapable of forming foci in this assay, both df heterozygous and wild-type shChd5-2 MEFs that expressed Ras readily formed foci. These analyses indicate that heterozygous deficiency of D4Mit190-51 and specific knockdown of Chd5 sensitize . dp heterozygous MEFs infected with a retroviral construct expressing either GFP or shp53 (left) were assayed for proliferation (right Arf in response to Ras was even more robust in MEFs in which p53 had been knocked down, as reported previously (Lowe and Sherr, 2003) , expression of p19
Arf in Ras-expressing df heterozygous MEFs was severely diminished ( Figure 6C, middle) . Importantly, specific knockdown of Chd5 caused a compromise in Ras-mediated induction of p19
Arf that closely paralleled that of df heterozygous cells. Ras-mediated induction of p16 Ink4a was also substantially reduced at the protein level in response to Ras both in cells heterozygous for the D4Mit190-51 deletion and in cells rendered deficient for Chd5 by RNAi-mediated knockdown. To extend these findings, we analyzed df heterozygous, wild-type, and dp heterozygous MEFs for p19 Arf and p16 Ink4a expression by immunofluorescence ( Figure 6C , right). This analysis revealed that expression of both p19 Arf and p16 Ink4a was compromised and enhanced in df heterozygous and dp heterozygous cells, respectively, supporting the finding that Chd5 positively regulates the Ink4/Arf locus.
To functionally validate the hypothesis that Chd5 modulates proliferation by facilitating p19 Arf , we used RNAi to deplete p19
Arf in dp heterozygous MEFs ( Figure 6D ). Remarkably, knockdown of p19 Arf bypassed the proliferation defect of dp heterozygous cells, and proliferation assays revealed that dp heterozygous MEFs in which p19
Arf was knocked down proliferated more efficiently than GFP-infected control cells (p = 0.005) and achieved proliferation levels comparable to that of Chd5 knockdown (p = 0.435).
In contrast, knockdown of p16 Ink4a caused dp heterozygous cells to proliferate only slightly better than controls (p = 0.15). These analyses provide functional evidence that p19 Arf is maintained by a gene within the D4Mit190-51 interval. This supports the notion that Chd5 maintains p53 levels by facilitating expression of p19 Arf and that deficiency of Chd5 predisposes to malignant transformation by compromising the p19 Arf /p53 pathway.
Chd5 Is a Tumor Suppressor Gene Consistent with the above findings suggesting that Chd5 is a potent tumor suppressor, we found that df heterozygous mice are prone to spontaneous tumors ( Figure 6E ; Table  S2 ). Squamous cell carcinoma, lymphoma, and hibernoma (a mesenchymal neoplasm) have been found in the df heterozygous cohort. This neoplasm provides evidence that the MEF phenotypes described in this study are relevant to tumorigenisis in an in vivo setting. Chd5 is expressed in cells that form tumors when 1p36 is deleted as well as in cell types that give rise to the tumors we observed in df heterozygous mice ( Figure S10 ). To examine if tumors from df heterozygous mice retain the wild-type allele, genomic DNA was subjected to Southern analysis ( Figure 6E, right) . This analysis demonstrated that the wild-type chromosome is retained in this tumor. Together, these findings indicate that heterozygosity of D4Mit190-51 predisposes to malignancy in vivo. To demonstrate that Chd5 is a tumor suppressor, we asked whether Chd5 deficiency predisposes to tumorigenesis in vivo in athymic nude mice. Control MEFs (wild-type GFP and wild-type shDnajc) failed to form tumors (0 neoplasms/10 injections), whereas p53 knockdown MEFs formed robust tumors (10 neoplasms/10 injections) (data not shown). In contrast, both df heterozygous cells and wild-type MEFs in which Chd5 was specifically knocked down formed tumors readily (20 neoplasms/20 injections and 11 neoplasms/12 injections, respectively) ( Figure 6F ). These studies conclusively demonstrate that Chd5 functions as a tumor suppressor.
CHD5 Is Deleted in Human Tumors
After having shown that Chd5 is a tumor suppressor in mice, we asked if CHD5 functions in human cancer by (B) p53 deficiency in vivo. Litters including dp heterozygous; p53 +/À (black asterisks) and corresponding Southern analysis (upper right). dp heterozygous; p53 À/À mice (lower left; red asterisks) were identified by PCR (lower right). Southern, lanes 1 and 2, wild-type; lanes 3-5, p53
; lane 6, dp heterozygous; p53 +/À . Endogenous (E), targeted (T) p53 alleles are shown, as well as the p53 pseudogene (P). PCR, lane 1, dp heterozygous; p53 analyzing expression of genes mapping to chromosome 1p in a panel of 54 human gliomas (Bredel et al., 2005b) ( Figure 7A ). CGHPRO data analysis tools (Chen et al., 2005) and a circular binary segmentation algorithm (Olshen et al., 2004) were used to define deletions. This analysis mapped CHD5 to a 5.4 Mb minimal common deletion region (MCR) between 1p36.32 and 1p36.22. The corresponding gene expression portraits (Bredel et al., 2005a) were used to compare CHD5 expression in normal human brain and in tumors with or without CHD5 deletion ( Figure 7B ). Whereas nondeleted tumors expressed CHD5 at levels comparable to normal brain (p = 0.66, independent t test), tumors with deletion had a significant decrease in CHD5 expression (p = 0.00006) ( Figure 7B ). The narrow range of CHD5 expression in deleted tumors contrasts markedly with the much wider range in tumors without deletion. To assess if there is a significant association between gene dosage and CHD5 expression in the tumors, we used an integrative strategy that combines a modification of signal-to-noise ratio computation and permutation testing (Juric et al., 2007) in deleted versus morphology-matched nondeleted tumors. The measure of statistical significance in terms of the false discovery rate (the q value) (Storey and Tibshirani, 2003 ) discloses significance for the genetic level in driving expression levels of CHD5 in the tumors (q < 0.05). These findings are consistent with our studies that identify Chd5 as a tumor suppressor and pinpoint deletion of the 1p36 interval encompassing CHD5 as an initiating event in tumorigenesis.
DISCUSSION
Rearrangements of 1p were first discovered in 1977 (Brodeur et al., 1977) . Since then, 1p36 deletions have been shown to be common in end-stage tumors of epithelial, neural, and hematopoietic origin (Bello et al., 1995; Bieche et al., 1993; Moley et al., 1992; Mori et al., 1998; Poetsch et al., 2003; Praml et al., 1995; White et al., 1995; White et al., 2005) . Despite extensive efforts, this gene had not been identified. We predicted that deletions encompassing a potent tumor suppressor locus would compromise tumor-suppressive mechanisms and predispose to cancer, thereby functionally pinpointing novel tumor suppressors to a defined region of the genome. In addition to generating loss-of-function models, the chromosomeengineering approach produced gain-of-function models, allowing us to directly compare the phenotype caused by decreased and increased dosage, respectively. This work has several major findings. First, we identify the D4Mit190-51 region as a potent regulator of proliferation, senescence, and apoptosis. We found an inverse correlation between dosage of this region and cellular proliferation. While increased dosage triggers the tumorsuppressive mechanisms of cellular senescence and apoptosis, decreased dosage of the same region enhances immortalization, increases spontaneous foci formation, and renders cells sensitive to oncogenic transformation. Second, we demonstrate that D4Mit190-51 positively regulates p53 via p19 Arf . We found that the enhanced senescence and apoptosis caused by increased dosage of the D4Mit190-51 region is p53 dependent, both in cultured cells and in vivo, demonstrating that p53 function is exacerbated by increased dosage of this region. On the other hand, p53 function is severely compromised by heterozygosity of D4Mit190-51, thereby facilitating oncogenic transformation in cultured cells and predisposing to spontaneous tumorigenesis in vivo. We demonstrate that D4Mit190-51 deficiency cripples both basal-and oncogene-induced expression of p16
Ink4a /p19 Arf , suggesting a mechanism for both compromised p53 function and susceptibility to transformation. Third, we identify Chd5 as the gene within D4Mit190-51 that regulates proliferation and mediates tumor-suppressive mechanisms. Indeed, depletion of Chd5 rescues the proliferative defect of cells with increased dosage of D4Mit190-51, indicating that enhanced expression of Chd5 alone is responsible for the proliferative defect of these cells. Importantly, knockdown of Chd5 in wild-type cells phenocopies cells with an engineered deletion of D4Mit190-51 with regards to enhanced proliferation; sensitivity to oncogenic transformation; compromised expression of p16 Ink4a , p19 Arf , and p53; and ultimately tumorigenesis. Fourth, we map CHD5 to an MCR in human tumors and uncover a frequent correlation between deletion of this region and reduced CHD5 expression. These findings (Figure 8 ) functionally identify CHD5 as a novel tumor suppressor mapping to human 1p36. Chd5 is a member of the chromodomain superfamily that consists of a large number of proteins with chromatin organizing modulator (chromo) domains (Thompson et al., 2003) . In mammals, this superfamily can be subdivided into five families based on the presence of specific protein motifs that endow each family of proteins with unique function (Jones et al., 2000) . For example, the Pc-G family-first identified as the human homolog of Drosophila Polycomb (Pc), a transcriptional repressor of homeotic genes-contains a Pc box, whereas the Chd family is characterized by the presence of SWI/SNF-type helicase/ATPase-and DNA binding domains.
The Chd family is further subdivided into subfamilies based on the absence (Chd1/2) or the presence (Chd3/ 4/5) of two Zn binding plant homeodomain (PHD) fingers. The PHD finger of the nucleosome-remodeling factor NURF was recently reported as a domain that interacts with H3K4-trimethylated histones-a mark of transcriptionally active chromatin, suggesting that this domain facilitates transcriptional activation (Wysocka et al., 2006) . Thus, Chd proteins such as Chd5 possess a unique combination of chromo, helicase, and DNA binding motifs. This suggests that Chd5 may function similarly to other chromodomain proteins that epigenetically modify chromatin to regulate gene expression networks affecting development, stem cell fate, and cancer (Valk-Lingbeek et al., 2004) .
Identifying Chd5 as a tumor suppressor functionally validates and extends the idea that chromatin remodeling proteins function in cancer. How might a chromatin remodeling protein such as Chd5 modulate tumor suppression? In exploring the mechanism whereby Chd5 modulates p53, we discovered that p19 Arf , an upstream inducer of p53 that is activated by oncogene-induced pathways (Lowe and Sherr, 2003) , is severely compromised by Chd5 deficiency. Since p19
Arf sequesters Mdm2, a negative regulator of p53, Chd5 deficiency compromises p53 and facilitates tumorigenesis. p19 Arf and p16 Ink4a are encoded by Ink4/Arf, one of the most commonly inactivated loci in human cancer (Esteller 
et al., 2001). p16
Ink4a facilitates Rb-whereas p19 Arf stimulates p53-mediated tumor-suppressive pathways. Activated oncogenes induce expression of both p19
Arf and p16 Ink4a , thereby protecting from malignancy (Serrano et al., 1997) . Importantly, Ink4/Arf is transcriptionally silenced by several Pc-G proteins such as Bmi-1, Cbx7, Ring1b, and Ezh2 (Gonzalez and Serrano, 2006) .
We found that p19 Arf expression at both transcript and protein level is compromised in Chd5-deficient cells. The inability of Ras to induce expression of p19
Arf that is proportional to the extent of p53 deficiency indicates that Ink4/Arf is inaccessible in Chd5-compromised cells, an idea supported by the finding that expression of p16
Ink4a is also severely diminished by Chd5 deficiency. These findings support a model in which the chromatin-remodeling activity of Chd5 is required for appropriate transcriptional activation of Ink4/Arf. Chd5's role as a tumor suppressor is consistent with our finding that CHD5 maps within an MCR in human cancer. Our findings are in line with previous studies that have reported 1p36 deletions in human cancer that include CHD5 (Bello et al., 1995; Bieche et al., 1993; Moley et al., 1992; Praml et al., 1995; White et al., 1995; White et al., 2005) . Several studies have identified relatively small deletions that include CHD5 and found reduced expression of CHD5 and other candidate genes in tumor cell lines (Law et al., 2005; Thompson et al., 2003; White et al., 2005) .
Our analyses revealing that Chd5 is a potent tumor suppressor functionally validate the hypothesis that deletions of 1p36 initiate tumorigenesis. Furthermore, our finding that Chd5 deficiency cooperates with activated Ras is in line with the observation that deletion of CHD5 and amplification of NMYC are genetically linked (Thompson et al., 2003) . Although Chd5 appears to be the sole tumor suppressor within the D4Mit190-51 interval, our studies do not exclude the possibility that additional tumor suppressor genes corresponding to human 1p36 mapping to regions flanking the D4Mit190-51 region exist. Loss of heterozygosity studies identified deletions that map outside the D4Mit190-51 region (Mori et al., 1998; Poetsch et al., 2003) . Whether or not these flanking deletions also initiate tumorigenesis awaits functional studies such as the ones described in this report.
We found that heterozygosity of Chd5 predisposes to malignancy and that the wild-type locus appears to be retained in immortalized cells as well as in spontaneous tumors. Retention Chd5 suggests a mechanism that deviates from Knudsen's two-hit hypothesis (Knudsen, 1971) . Indeed, analysis of neuroblastoma cell lines with 1p deletions identified only a single missense mutation within Chd5, consistent with the hypothesis that complete inactivation of Chd5 by mutation is not a prerequisite for tumorigenesis (Thompson et al., 2003) . This could explain why studies that used loss of expression as the criterion for validating tumor-suppressive function may have missed CHD5 as a likely candidate.
Identification of Chd5 as a tumor suppressor is the first demonstration, to our knowledge, that a member of the Chd family of chromatin-remodeling proteins functions in tumorigenesis. Other members of the chromodomain superfamily, however, have well-established roles in cancer. Bmi-1, for example, is an oncogene that cooperates with activated Ras to transcriptionally repress Ink4/Arf (Jacobs et al., 1999) . Thus, the Ink4/Arf locus appears to be a common target for epigenetic modulation by diverse chromodomain-containing proteins.
Pc-G members such as Bmi-1 have been implicated as transcriptional repressors, and Pc specifically recognizes H3K27-trimethylated histones, a mark of silenced chromatin (Cao et al., 2002; Muller et al., 2002) . In contrast, Chd1 specifically interacts with H3K4-trimethylated histones, marks of transcriptionally active chromatin (Flanagan et al., 2005; Pray-Grant et al., 2005) . Although both Chd1 and Chd5 are distant members of the Chd family, they share the SWI/SNF-helicase motif, which can facilitate gene activation (Jones et al., 2000) . Pc, on the other hand, represses transcription by recruiting chromatinremodeling proteins that make the chromatin inaccessible to SWI/SNF-helicase/ATPase activity. Whether or not antagonism between Pc-G and Chd proteins exists has not been explored. We propose a model in which Chd5 maintains chromatin in a transcriptionally active state that facilitates expression of p16
Ink4a and p19 Arf , thus providing tumor suppression. Although we have focused on the p19
Arf /p53 arm of the Chd5-mediated pathway, we demonstrate that expression of p16
Ink4a is also reduced in Chd5-deficient cells, raising the possibility that p16
Ink4a /Rb-mediated pathways are also compromised by Chd5 deficiency. Although further investigation of this hypothesis is warranted by using the models described herein, it is intriguing that the first tumor found in df heterozygous mice was an SCC of the skin, a tumor that rarely develops in p53-compromised mice (Donehower et al., 1992) 
that p19
Arf /p53-independent pathways are compromised by Chd5 deficiency. Whether or not Chd5 is required for expression of p16
Ink4a and p19 Arf in diverse cell types, and whether Chd5 maintains stem cells as has been elegantly demonstrated for Bmi-1 (Bruggeman et al., 2005) , remains to be explored.
In summary, chromosome engineering has been invaluable for functionally identifying CHD5 as a tumor suppressor mapping to 1p36. Chd5 deficiency predisposes to malignancy by crippling tumor-suppressive pathways involving p16
Ink4a , p19 Arf , and p53. The idea that this chromodomain protein epigenetically regulates the Ink4/Arf locus draws notable parallels, yet striking contrasts, with the function of members of the Pc-G family of chromodomain proteins. This work defines a previously unrecognized role for CHD5 in cancer. We propose that CHD5 facilitates transcriptional programs that provide tumor suppression and that compromised CHD5 provides a common underlying mechanism for initiating tumorigenesis in diverse types of human cancer.
EXPERIMENTAL PROCEDURES
Chromosome Engineering AB2.2 ES cells (129S5 strain) were electroporated with $25 mg of the pTVD4Mit190 or pTVD4Mit51 insertion vectors, clones were selected in G418 (180 mg/ml) or puromycin (3 mg/ml) for 8-10 days, and targeting was assessed by Southern. Doubly targeted clones were electroporated with the Cre plasmid pOG231, and clones were selected in HAT (0.1 mM sodium hypoxanthine, 0.2 uM aminopterin, and 0.016 mM thymidine), released in HT (0.1 mM sodium hypoxanthine and 0.016 mM thymidine) for 48 hr, and H R G R P R df/dp clones identified.
Mouse Strains df/dp clones were established as mouse strains, and F1 progeny from chimera X C57BL/6J crosses were genotyped by PCR or Southern. df/dp X p53 +/À crosses were genotyped as described (Donehower et al., 1992) . PCR was performed with 10 ng genomic DNA using a MasterCycler gradient thermocycler (Eppendorf) and reaction products resolved on 2%-4% agarose gels. Primers are shown in Table S4 .
Cellular Assays
MEFs were generated and assessed for proliferation by plating 1 3 10 5
MEFs on 6-well dishes and harvesting and counting plates in triplicate at 2 day intervals using a Z1 Coulter particle counter (Beckman-Coulter). Immortalization was assessed by serially passaging 2 3 10 5 cells every 3 days. Graphing and standard error were performed with Prism. Cell cycle analysis was performed by flow cytometry using a BD LSRII (BD Biosystems) and FACS DiVa (BD Biosystems). The SA-b-gal assay was performed as previously described. Foci formation was performed by growing cells at high density. Ras-infected cells were assayed for transformation by staining colonies in crystal violet and by anchorage-independent growth in 0.4% soft agar. Tumorigenesis assays in athymic nude mice were performed as described previously (Hemann et al., 2004) .
Histological Analysis and TUNEL Assays
Tissues were harvested by using standard procedures and pathology assessed by H.V. Unstained sections were analyzed for apoptosis using TUNEL (Amersham) according to the manufacturer's protocol.
RNAi shRNAs (see Table S3 ) were cloned in the MSCV-U6miR30-PIGDRI (Dickins et al., 2005) with Ras or GFP (pMSCV-puro-PIG) (Hemann et al., 2003) . Retrovirus was produced by transfecting Phoenix cells (G. Nolan, Stanford University) with shRNAs for 48 hr, the cells fed with media (DMEM, 10% FBS, 1% penicillin/streptomycin), and MEFs infected for 12 hr with viral supernatant and selected for 6-8 days. shRNA constructs for p53 and p16 Ink4a have been described previously (Dickins et al., 2005; Keyes et al., 2005) .
Real-Time PCR Total RNA was isolated with Trizol reagent (GIBCO), RT-PCR performed on 0.5 mg total RNA using a Superscript first-strand cDNA synthesis kit (Invitrogen), and real-time PCR performed using a Peltier Thermal cycler (MJ Research) and a SYBR Green PCR kit (Applied Biosystems). Samples were analyzed in triplicate, and expression was compared to b-actin. Primers are shown in Table S4 .
Western Analysis
MEFs were solubilized in Laemmli buffer and quantitated using a protein assay (Bio-Rad), and 10-20 mg protein was analyzed by using standard procedures, with antibodies for specific for Ras (mouse monoclonal, BD Transduction Laboratories, 1:500), p19 (Ab80, rabbit polyclonal, Abcam, 1:1000), p16 (M156, rabbit polyclonal, Santa Cruz, 1:500), p53 (CM5, Vector Laboratories, 1:500), and b-actin (AC-15, mouse monoclonal, Sigma, 1:10000). Secondary antibodies were goat anti-mouse-HRP (IgG and IgM)-and goat anti-rabbit-HRP (IgG; Pierce, 1:5000).
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